Ticagrelor influences the way blood cells interact. Reducing the tendency of these cells to clump keeps pathways clear, protecting the heart from blockages that cause pressure.
When a blood clot begins to form after a heart event, doctors often turn to medicines that keep platelets from sticking together. Ticagrelor belongs to the antiplatelet class, meaning it helps reduce the chance of new clots developing. It is the active compound in several brand-name products, most notably Brilinta, which is widely used in Singapore.
This chemical is a reversible inhibitor of the P2Y12 receptor on platelets. By blocking this receptor, ticagrelor interferes with the signal that tells platelets to clump, thereby lowering the risk of blockages in arteries. Its rapid onset of action and consistent effect make it a common choice for patients who need prompt protection after cardiac procedures.
In Singapore, ticagrelor-containing tablets are regulated as medicines and are available only under professional supervision. While the ingredient itself does not cure heart disease, it assists with managing the risk of clot-related complications when incorporated into an overall treatment plan.
In Singapore, the tablet known as Brilinta includes ticagrelor as its active ingredient. Brilinta is offered in standard tablet form, typically 90 mg each, and is taken by mouth. Generic versions may also be available, but they contain the same ticagrelor molecule and are subject to the same safety standards.
Beyond Brilinta, ticagrelor appears in other formulations such as oral suspension for patients who have difficulty swallowing tablets. The core difference among these products lies in the dosage strength and the packaging, not in the active compound itself.
People who have experienced a heart attack often receive ticagrelor to help keep blood flowing smoothly. It is also recommended for individuals with unstable angina-a painful chest condition caused by reduced blood supply to the heart. After a coronary stent is placed to open a narrowed artery, ticagrelor helps prevent the stent from becoming blocked again.
Patients with certain types of peripheral artery disease may be prescribed ticagrelor to lower the chance of serious clot events. Lastly, some clinicians consider it for high-risk patients who have multiple cardiovascular risk factors, as part of a broader antiplatelet strategy.
By attaching to the P2Y12 receptor on platelets, ticagrelor blocks the signal that triggers clotting. This blockade is reversible, which means its effect can wane if the medication is stopped, allowing normal clotting to resume when appropriate. The result is a steady, predictable reduction in platelet activity, helping to keep arteries open without completely disabling the body’s natural clotting ability.
Mild bruising or small nosebleeds can appear, especially when the medication is first started. Some people notice shortness of breath or a slight headache, which usually improves with continued use.
Rarely, severe bleeding may occur, such as gastrointestinal bleeding or bleeding in the brain. Signs include unusual swelling, dark stools, or a sudden drop in blood pressure, and these require urgent medical attention.
Ticagrelor should be avoided in individuals with active internal bleeding, a recent brain hemorrhage, or severe liver disease. Pregnant or breastfeeding women are generally advised not to use it, and people with known allergies to the ingredient must also steer clear.
Alcohol can increase bleeding risk when taken with ticagrelor. Certain medicines, like some antidepressants and anticoagulants, may also heighten this risk. Always check the medication’s label or package insert for a complete list of possible interactions.
When storing ticagrelor-containing tablets, keep them in a dry place away from direct sunlight and out of reach of children. The typical treatment course can range from several months to a year, depending on the underlying condition and the specific product, such as Brilinta. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This article provides an educational overview of ticagrelor and is not medical advice. Medicines containing this ingredient, such as Brilinta, may differ in formulation, strength, and directions, and the information herein does not substitute professional guidance. No liability is assumed for any clinical decisions made based on this content. Readers should review the labeling of their specific medication and seek guidance from a qualified healthcare professional.
For more details, consult the following resources:
